Dr. Seth Baum was highly paid by Aegerion. Now he is highly paid by Amgen. He proposed an algorithm for identifying FH patients. He is also treasurer for the FH Foundation, a charity funded by big pharma, and this foundation also promotes an algorithm. The word “Algorithm” sounds sophisticated and full of the future. But a common recipe for chocolate chip cookies is an algorithm. Setting this FH scheme to the tune of an “algorithm,” applied to a computer database of patients, only leverages the consequences of the error. Reading the pharma-funded reports, it is at the highest priority to keep the scoring systems front and center and genetic testing at a lower priority … just barely in there to locate those who would otherwise be left behind. Although identifying the lower scoring, milder FH is of high value, correctly diagnosing the severe non-FH within those FH phenotypic results should not be neglected. This extensive pattern of emphasizing the non-genetic approach to this admittedly genetic disease suggests orchestration and coordination.